Skip to main content

Table 1 Effect of 17-AAG on tumour volume

From: Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy

 

Tumour volume (% of day 0) at day 4 (N)

P compared to day 0

Tumour volume (% of control) at day 4)

P compared to Control at day 4

Control

128.4 ± 5.9 (11)

0.0007

  

17-AAG (20mg/kg)

88.5 ± 2.9 (11)

0.003

68.9%

<0.0001

17-AAG (40mg/kg)

67.0 ± 3.6 (10)

<0.0001

52.2%

<0.0001

17-AAG (80mg/kg)

42.1 ± 7 (6)

0.0004

32.8%

<0.0001

  1. Effect of 3 daily doses of 17-AAG (20mg/kg, 40mg/kg, 80mg/kg) or vehicle only (control) on tumour volume in MMTV-NEU-NT transgenic mice. Tumour volume expressed as a % of day 0 (column 2), p values: day 4 vs day 0. Tumour volume also expressed as a % of control cohort at day 4 (column 4), p values: treated day 4 vs control day 4. Mean tumour volume at day 0 of the 4 cohorts was 0.59 ± 0.08 cm3 (control), 0.67 ± 0.07 cm3 (20mg/kg), 0.67 ± 0.08 cm3 (40mg/kg) and 0.61 ± 0.12 cm3 (80mg/kg). Data are presented as the mean ± SEM.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us